Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 8/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008927 | 0.96 | POLB (0.73) | POLBMEN1KMT2ATDP1RAB9A | |
| SCHEMBL12008856 | 0.91 | NPC1 (0.63) | POLBMEN1KMT2ATDP1RAB9A | |
| SCHEMBL13746177 | 0.88 | POLB (0.61) | POLBMEN1KMT2ATDP1RAB9A | |
| SCHEMBL12008911 | 0.81 | FFAR1 (0.70) | POLBMEN1KMT2ATDP1RAB9A | |
| SCHEMBL12008888 | 0.80 | CASP3 (0.76) | POLBMEN1KMT2ARAB9AGPR55 | |
| SCHEMBL12008893 | 0.79 | KMT2A (0.65) | POLBMEN1KMT2AGPR55NPC1 | |
| SCHEMBL12008863 | 0.79 | KMT2A (0.74) | POLBMEN1KMT2ATDP1GPR55 | |
| SCHEMBL12008913 | 0.78 | MEN1 (0.77) | POLBMEN1KMT2ATDP1GPR55 | |
| SCHEMBL12008983 | 0.77 | POLB (1.00) | POLBMEN1KMT2ATDP1RAB9A | |
| SCHEMBL12008832 | 0.77 | MEN1 (1.00) | POLBMEN1KMT2ATDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | DASGUPTA RAMANUJ (US) | 2017-02-23 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9433611-B2 | Oxazole and thiazole compounds as β-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9173871-B2 | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY | 2013-05-02 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264744-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | POLB 2397/4885MEN1 3747/4885KMT2A 4503/4885 |
| US-20170049751-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | POLB 2088/4885MEN1 4655/4885KMT2A 4591/4885 |
| US-20130109675-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF | CTNNB1, CTNNA1, CTNNBL1 | POLB 2088/4885MEN1 4655/4885KMT2A 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.